CN104147268B - 一种治疗肝胆结石的中药组合物及其制剂 - Google Patents
一种治疗肝胆结石的中药组合物及其制剂 Download PDFInfo
- Publication number
- CN104147268B CN104147268B CN201410423918.7A CN201410423918A CN104147268B CN 104147268 B CN104147268 B CN 104147268B CN 201410423918 A CN201410423918 A CN 201410423918A CN 104147268 B CN104147268 B CN 104147268B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- liver
- preparation
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 210000000232 gallbladder Anatomy 0.000 title abstract description 21
- 230000002440 hepatic effect Effects 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 210000004185 liver Anatomy 0.000 claims description 42
- 210000000941 bile Anatomy 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 23
- 239000004575 stone Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 7
- 241000218176 Corydalis Species 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000036407 pain Effects 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract 1
- 238000007599 discharging Methods 0.000 abstract 1
- 201000001883 cholelithiasis Diseases 0.000 description 14
- 239000013641 positive control Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000035568 catharsis Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 208000019802 Sexually transmitted disease Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000003445 biliary tract Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 201000001352 cholecystitis Diseases 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 125000000017 cortisol group Chemical group 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010008635 Cholestasis Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003809 bile pigment Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007870 cholestasis Effects 0.000 description 2
- 231100000359 cholestasis Toxicity 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000031868 Calculus ureteric Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000002513 Flank pain Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 208000000014 Ureteral Calculi Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 210000001096 cystic duct Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- BEGBSFPALGFMJI-UHFFFAOYSA-N ethene;sodium Chemical group [Na].C=C BEGBSFPALGFMJI-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013360 fish flour Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 239000008812 xiaoyanlidan Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
治愈 | 有效 | 治愈率 | 有效率 | |
治疗组 | 282例 | 330例 | 78.33% | 91.67% |
对照组 | 186例 | 234例 | 51.96% | 65.36% |
组别 | n | BA | Ca | TBIL | DBIL |
正常组 | 10 | 574.81±110.23 | 2.24±0.57 | 1.25±0.19 | 0.63±0.25 |
模型组 | 10 | 254.64±62.75▲▲ | 4.75±1.27▲▲ | 2.58±0.24▲▲ | 1.03±0.25▲▲ |
阳性对照 | 10 | 386.61±67.46* | 4.17±1.26* | 1.70±0.22* | 0.96±0.22 |
组合物低组 | 10 | 380.63±75.61** | 3.82±0.99** | 1.81±0.15* | 0.75±0.25* |
组合物中组 | 10 | 452.75±76.45**△ | 3.57±0.77**△ | 1.44±0.17**△ | 0.73±0.13**△ |
组合物高组 | 10 | 534.36±53.19**△ | 2.75±0.45**△ | 1.32±0.14**△ | 0.66±0.13**△ |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410423918.7A CN104147268B (zh) | 2014-08-26 | 2014-08-26 | 一种治疗肝胆结石的中药组合物及其制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410423918.7A CN104147268B (zh) | 2014-08-26 | 2014-08-26 | 一种治疗肝胆结石的中药组合物及其制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104147268A CN104147268A (zh) | 2014-11-19 |
CN104147268B true CN104147268B (zh) | 2015-04-29 |
Family
ID=51873032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410423918.7A Expired - Fee Related CN104147268B (zh) | 2014-08-26 | 2014-08-26 | 一种治疗肝胆结石的中药组合物及其制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104147268B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104815161A (zh) * | 2015-04-27 | 2015-08-05 | 青岛辰达生物科技有限公司 | 一种治疗前列腺增生合并肾结石的中药组合物及制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103736018A (zh) * | 2013-12-31 | 2014-04-23 | 李政 | 一种治疗胆结石的药物及其制备方法 |
-
2014
- 2014-08-26 CN CN201410423918.7A patent/CN104147268B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN104147268A (zh) | 2014-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103830577B (zh) | 一种治疗肝胆结石和肾结石的药物组合物及其用途 | |
CN105031559B (zh) | 一种治疗由多囊卵巢综合征引起不孕症的中药 | |
CN102240318B (zh) | 一种益气增乳中药的制备方法和分析方法 | |
CN1692939B (zh) | 治疗乳腺增生的中药复方制剂及其制备方法 | |
CN109528980A (zh) | 一种用于治疗卵巢储备功能下降疾病的中药组合物及其制药应用 | |
CN104043042A (zh) | 一种治疗肝胆结石的中药组合物及其用途 | |
CN103585583B (zh) | 一种治疗肝胆结石的中药组合物及其用途 | |
CN101664533B (zh) | 一种治疗急慢性乳腺增生的中药及制备方法 | |
CN104147268B (zh) | 一种治疗肝胆结石的中药组合物及其制剂 | |
CN101066417A (zh) | 孕康口服液在制备治疗妇女月经不调药物中的用途 | |
CN104548016A (zh) | 一种中药组合物在制备治疗高尿酸血症药物中的用途 | |
CN1951430A (zh) | 一种治疗银屑病和红斑狼疮的复方中药 | |
CN104352629B (zh) | 一种治疗肝胆结石的中药组合物及其用途 | |
CN101559196B (zh) | 一种治疗乳腺增生的药物及其制备方法 | |
Park et al. | Dangnyohwan improves glucose utilization and reduces insulin resistance by increasing the adipocyte-specific GLUT4 expression in Otsuka Long-Evans Tokushima Fatty rats | |
CN104587316B (zh) | 抗痛风组合物及其制备方法和应用 | |
CN105535408A (zh) | 一种治疗胆固醇结石的药物组合物及其用途 | |
CN101239167B (zh) | 一种治疗子宫肌瘤的药物 | |
CN105288344A (zh) | 一种用于治疗肝胆结石的中药组合物及其应用 | |
CN102961676B (zh) | 一种治疗胆结石、胆囊炎的中药制剂及其制备方法 | |
CN112656867A (zh) | 一种治疗异常子宫出血的中药组合物及其制备方法 | |
CN102961678B (zh) | 一种治疗胆结石、胆囊炎的中药制剂及其制备方法 | |
CN116531469A (zh) | 一种用于宠物下泌尿综合症的治疗药物及其应用 | |
CN102961680B (zh) | 一种治疗胆结石、胆囊炎的中药制剂及其制备方法 | |
CN114306523A (zh) | 治疗痛风肾病的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: CHEN HONG Free format text: FORMER OWNER: WANG SHENJIAN Effective date: 20150213 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ren Zhiguo Inventor before: Wang Shenjian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG SHENJIAN TO: REN ZHIGUO Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 266000 QINGDAO, SHANDONG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150213 Address after: 266000 Qingdao City, Sifang District, Shandong flood water ditch village, No. 2, 106 Applicant after: Chen Hong Address before: 276017 Luozhuang Province, Linyi District, Zhao Zhao Road, No. 1072 Applicant before: Wang Shenjian |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Ge Qiuju Inventor after: Liu Feng Inventor before: Ren Zhiguo |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160704 Address after: 257100, room 1, unit 61, building 33, 202 Ji'nan Road, Dongying District, Shandong, Dongying Patentee after: Ge Qiuju Address before: 266000 Qingdao City, Sifang District, Shandong flood water ditch village, No. 2, 106 Patentee before: Chen Hong |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150429 Termination date: 20160826 |